Cue Biopharma (NASDAQ:CUE) Issues Quarterly Earnings Results

Cue Biopharma (NASDAQ:CUE) announced its quarterly earnings results on Friday. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45), FiscalAI reports. The company had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%.

Cue Biopharma Stock Up 10.0%

CUE opened at $34.20 on Friday. Cue Biopharma has a 52 week low of $4.97 and a 52 week high of $45.50. The business’s 50 day moving average is $29.50 and its two-hundred day moving average is $147.28. The firm has a market cap of $143.64 million, a price-to-earnings ratio of -1.27 and a beta of 2.47.

Analyst Ratings Changes

A number of research firms recently commented on CUE. Wall Street Zen downgraded shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings raised shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Insider Buying and Selling at Cue Biopharma

In other news, CEO Shao-Lee Lin sold 18,258 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $28.62, for a total value of $522,543.96. Following the completion of the sale, the chief executive officer directly owned 705,995 shares of the company’s stock, valued at approximately $20,205,576.90. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 14.56% of the company’s stock.

Institutional Trading of Cue Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of CUE. Boothbay Fund Management LLC boosted its stake in Cue Biopharma by 15.3% during the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares during the period. Stifel Financial Corp increased its stake in Cue Biopharma by 25.4% in the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after purchasing an additional 50,000 shares during the period. Squarepoint Ops LLC acquired a new position in Cue Biopharma in the third quarter valued at $62,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after buying an additional 73,000 shares during the last quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.